• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Animal & Veterinary

  • Print
  • Share
  • E-mail

FDA APPROVES FIRST TOPICAL DRUG FOR HEARTWORM PREVENTION IN DOGS AND CATS

FDA Veterinarian Newsletter September/October 1999 Volume XIV, No V

FDA has approved the first topical drug -- RevolutionTM, Selamectin, for the prevention of heartworm disease in dogs and cats six weeks of age and older. RevolutionTM is also the first drug to combine heartworm prevention as well as the prevention and control of adult fleas and their eggs. Although heartworms and fleas are the most significant parasites that RevolutionTM has activity against, the drug is also effective against ear mites in cats and dogs, sarcoptic mange (also known as scabies) in dogs, and intestinal roundworm and hookworm infections in cats.

The drug is applied topically once a month. The duration of treatment depends on the type of parasitic infection. In clinical trials, RevolutionTM was shown to be safe and effective, with minimal side effects, and was well tolerated by healthy dogs and cats. Caution must be used when treating sick, debilitated or underweight animals. RevolutionTM will be sold by Pfizer Inc. of New York, N.Y. beginning this fall. It will be available only on the order of a licensed veterinarian.